ArticleBlood cancer journal2026
MGUS prevalence among active-duty military personnel.
Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is a precursor condition for multiple myeloma, and although environmental exposures have been implicated in its pathogenesis, it is unknown whether exposure to open-air burn pits used during U.S. military operations in Iraq affects prevalence of MGUS in active-duty service members (ADSMs). ADSMs represent a distinct young and physically fit population, with higher proportions of male and Black individuals compared to the general U.S. population. This retrospective cohort study evaluated MGUS prevalence among ADSMs. Participants included ADSMs deployed to Iraq with self-reported burn pit exposure (DEP-IQ; n = 534), ADSMs deployed to Germany without burn pit exposure (DEP-DEU; n = 534), and non-deployed ADSMs (NON-DEP; n = 521). Eligibility criteria included deployment ≥180 days, age ≥35 years at deployment, and ≥10 years of continued military service. Serum samples collected 11-14 years post-deployment were analyzed using serum protein electrophoresis, immunofixation, and serum free light chain (sFLC) assays. MGUS and light-chain MGUS (LC-MGUS) prevalence were estimated using conventional and revised age-stratified sFLC reference intervals. MGUS + revised LC-MGUS prevalence did not differ between DEP-IQ (5.6%), DEP-DEU (4.3%), and NON-DEP (5.2%) cohorts. The overall total prevalence of MGUS + revised LC-MGUS was 5% and was higher in Black (10.4%) than White ADSMs (3.9%), p < 0.001. When using conventional sFLC reference intervals, LC-MGUS was more frequently identified among deployed ADSMs (1.6%) compared with non-deployed ADSMs (0.2%); however, this association was no longer significant when revised reference intervals were applied. These findings suggest that military service may involve cumulative or non-burn pit exposures contributing to plasma cell dysregulation. Application of updated sFLC reference ranges is critical to avoid overestimation of LC-MGUS. Long-term studies are warranted to define progression risk and inform targeted screening strategies in ADSMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.